CMB Genomics provides clinical diagnostic testing, next generation sequencing, and laboratory genetic testing services. It focuses on enhancing access to molecular diagnostics in Africa through genetic testing and training.

CENTRE FOR MOLECULAR BIOSCIENCES AND GENOMICS LIMITED

Illuminas provides research solutions in various industries including technology, financial services, and healthcare. Self-described capabilities include quantitative and qualitative research, advanced analytics, and data visualization.

Illuminas

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Qiagen N.V.

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and multiomics technology to build products for researchers and clinicians to advance science and medicine. The company manufactures G4 Instrument, a benchtop next generation sequencer to produce genetic sequencing results, as well as associated menu of consumable kits. It also offers PX Integrated Solution that combines single cell analysis, spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company has partnerships with Agilent Technologies, Dovetail Genomics, Lexogen, New England Biolab, QIAGEN, Roche, Twist Bioscience, and Watchmaker Genomics to validate their library preparation kits on the G4, as well as the Broad Institute of MIT and Harvard to connect the G4 to Terra platform, a data platform. Singular Genomics Systems, Inc. was incorporated in 2016 and is headquartered in La Jolla, California.

Metric
Company Name	CENTRE FOR MOLECULAR BIOSCIENCES AND GENOMICS LIMITED	Illuminas	Qiagen N.V.	Singular Genomics Systems, Inc.
Symbol			QGEN	OMIC
MSH ID	ORG:CMBGENOMICS	COM:ILLUMINAS	COM:QIAGEN	COM:SINGULARGENOMICS
Market	PRIVATE	PRIVATE	STOCKS	STOCKS
Sector	Healthcare & Health Services	Commercial & Professional Services	Healthcare	Healthcare
Industry	Biotechnology	Market Research	Medical - Diagnostics & Research	Medical - Instruments & Supplies
Country	KE	UK	NL	US
Stage
Employee Count			5.90K	255
Website	cmbgenomics.org	illuminas.com	qiagen.com	singulargenomics.com
LinkedIn			qiagen
Founders

Metric
Market Cap	9.10B	19.05M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	1.97B	2.91M
Revenue (LTM)
Revenue (NTM)
Gross Profit	1.22B	-558K
EBITDA	650.58M	-86.50M
Operating Income	445.25M	-102.80M
Net Income	341.30M	-94.82M
EPS	1.54	-1.30
Diluted EPS	1.53	-1.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.64	-0.19
Operating Profit Margin	0.24	-35.31
EBITDA Margin	0.33	-29.71
Net Profit Margin	0.17	-32.06
Return on Equity	0.09	-0.45
Return on Assets	0.06	-0.35
Return on Capital Employed	0.10	-0.42

ORG:CMBGENOMICS

CENTRE FOR MOLECULAR BIOSCIENCES AND GENOMICS LIMITED

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	29.01	-0.45
P/B Ratio	2.61	0.20
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.38	291.31
EV Multiple	23.42	0.36

Metric
Days Sales Outstanding	61.02	468.52
Days Payables Outstanding	39.03	326.35
Days Inventory Outstanding	210.93	1.43K
Operating Cycle	302.73	1.63K
Cash Conversion Cycle	259.01	1.35K
Asset Turnover	0.35	0.01

Metric
Operating Cash Flow	459.45M	-73.65M
Free Cash Flow	296.65M	-74.62M
Cash Flow to Debt	0.41	-0.98
Operating Cash Flow/Sales	0.30	-25.30
Free Cash Flow Yield	0.03	-1.91

Metric
Cash & Equivalents	668.08M	16.23M
Accounts Receivable	-55.12M	348K
Inventory	398.38M	13.57M
Goodwill	2.48B
Debt to Capitalization	0.29	0.32
Debt to Assets	0.25	0.27
Current Ratio	3.74	13.64
Quick Ratio	1.46	9.60

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.02	4.55
R&D to Revenue	0.10	18.05
SG&A to Revenue	0.06	9.08